Subsequently, patients who receive combined therapy with α-GalCer-loaded DCs, which can enhance iNKT cell activation, show increases in circulating iNKT cell numbers and IFN-γ production, with some patients achieving a partial anti-tumor response (102–104). The gene discussed is IFNG; the disease is neoplasm.